These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6373153)

  • 1. Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy.
    Pines A; Raafat H; Lynn AH; Whittington J
    Curr Med Res Opin; 1984; 8(10):734-42. PubMed ID: 6373153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.
    Stellon A; Davies A; Webb A; Williams R
    Postgrad Med J; 1985 Sep; 61(719):791-6. PubMed ID: 2997764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis].
    Yamada H
    Nihon Naibunpi Gakkai Zasshi; 1989 Jun; 65(6):603-14. PubMed ID: 2792461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged low-dose corticosteroid therapy and osteoporosis in rheumatoid arthritis.
    Hajiroussou VJ; Webley M
    Ann Rheum Dis; 1984 Feb; 43(1):24-7. PubMed ID: 6696513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
    Loddenkemper K; Grauer A; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2003; 21(1):19-26. PubMed ID: 12673885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.
    Pearce G; Ryan PF; Delmas PD; Tabensky DA; Seeman E
    Br J Rheumatol; 1998 Mar; 37(3):292-9. PubMed ID: 9566670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
    Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
    Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis.
    Tsugeno H; Tsugeno H; Fujita T; Goto B; Sugishita T; Hosaki Y; Ashida K; Mitsunobu F; Tanizaki Y; Shiratori Y
    Osteoporos Int; 2002 Aug; 13(8):650-6. PubMed ID: 12181624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.
    Noa M; Mendoza S; Más R; Mendoza N; León F
    Drugs R D; 2004; 5(5):281-90. PubMed ID: 15357627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005.
    Duyvendak M; Naunton M; Atthobari J; van den Berg PB; Brouwers JR
    Osteoporos Int; 2007 Oct; 18(10):1429-33. PubMed ID: 17323108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis.
    Naunton M; Peterson GM; Jones G; Griffin GM; Bleasel MD
    J Rheumatol; 2004 Mar; 31(3):550-6. PubMed ID: 14994404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
    Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
    Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
    Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis.
    Stendig-Lindberg G; Tepper R; Leichter I
    Magnes Res; 1993 Jun; 6(2):155-63. PubMed ID: 8274361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician's awareness of the prevention of corticosteroid induced osteoporosis.
    Ungprasert S; Wangkaew S; Louthrenoo W
    J Med Assoc Thai; 2007 Jan; 90(1):59-64. PubMed ID: 17621734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2005 Apr; 15(4):616-24. PubMed ID: 15802774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
    Reid IR; King AR; Alexander CJ; Ibbertson HK
    Lancet; 1988 Jan; 1(8578):143-6. PubMed ID: 2892989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteocalcin in the assessment of corticosteroid induced osteoporosis. Effect of long and short term corticosteroid treatment.
    Peretz A; Praet JP; Bosson D; Rozenberg S; Bourdoux P
    J Rheumatol; 1989 Mar; 16(3):363-7. PubMed ID: 2786081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
    Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.